CHA Biotech and LG CNS Establish Strategic Partnership Including Equity Investment
CHA Biotech Signs Strategic Agreement with Hanwha General Insurance and Hanwha Life Including Equity Investment
CHA Biotech Appoints Vice Chairman Cha Won-tae as Chief Executive Officer
CHA Bio Group Accelerates Portfolio Restructuring Through Sale of Solidus Investment to Focus on Core Businesses
CHA Bio Group Accelerates Portfolio Restructuring Focused on Core Businesses Through Sale of CHA Vaccine Institute Stake
CHA Biotech and Miltenyi Biotec Collaborate on CAR-NK Cell Therapy Development
CHA Biotech and Thermo Fisher Scientific Build Global Biotech Research Infrastructure for K-Bio CIC

2025

Matica Biotechnology Signs Strategic Agreement with Texas A&M University for CGT Research and Development
Matica Bio Labs Selected as an Executing Organization for the “2025 CMC Strategic Consulting” Project by the Korea Drug Development Fund
Consolidated Revenue Surpasses KRW 1 Trillion in 2024
Matica Biotechnology Signs CDMO Contract with U.S.-based Child’s Cure
Matica Biotechnology Signs Strategic Agreement with Texas A&M University for CGT R&D
CHA Biotech’s Phase I Clinical Trial for Premature Ovarian Failure Cell Therapy Confirms Safety
CHA Biotech’s TIL Cell Therapy for Recurrent Ovarian Cancer, ‘CHATIL,’ Selected as National New Drug Development Project
CHA Biotech’s ‘CHA Stem Cell Institute’ Named ‘Best Corporate Research Institute,’ Awarded by Ministry of Science and ICT
CHA Bio Group Holds Topping-out Ceremony for ‘CGB (Cell Gene Biobank)'
CHA Biotech and Sartorius Korea Biotech Sign MOU for Global Stem Cell Line Establishment and Large-scale Manufacturing Process Development
CHA Biotech and Miltenyi Biotec Korea Collaborate on Automated Large-Scale Manufacturing Process Development for CAR-NK Cells
Matica Biotechnology Signs Commercial Manufacturing Agreement with U.S.-based Company
Matica Biotechnology Signs AAV Vector Manufacturing Agreement with Surgium Biotech
Matica Biotechnology Signs CDMO Agreement with Calidi Biotherapeutics for Oncolytic Virus Therapy
CHA Bio Group Forms Strategic Partnership with Kakao in Digital Healthcare through Equity Exchange

2024

Matica Biotechnology initiates development of a pediatric brain tumor therapy in collaboration with U.S.-based Treovir
Matica Biotechnology develops a virus capsid separation and analysis method
Matica Biotechnology signs a letter of intent (LOI) with U.S.-based KaliVir Immunotherapeutics for CDMO services
Matica Biotechnology enters into CDMO agreements with U.S.-based CytoImmune Therapeutics and Mongoose Bio
Selection of CBT101, an immune cell therapy for solid tumors, for government support under the National New Drug Development Program
Achievement of ISO27001:2022 certification for international information security standards
Joint development with CHA Vaccine Institute on a cancer therapy combining NK cells and immune boosters
Technology transfer agreement with U.S.-based CanCure for MIC-targeted antibody technology
Matica Biotechnology appoints CEO Paul Kim, a leading biotech and investment expert
Patent secured for the production method and material for highly activated NK cells
Launch of research on the anticancer efficacy of NK cell therapy using cationic polymers
CDMO contract signed with Cell in Cells for organoid-based therapies
Expanded collaboration with Centenaire Biosciences for combination studies involving NK cells and antibodies

CHA Network

Company Name CHA Biotech Co., Ltd.
CEO Won Tae Cha

[Main Office] CHA Bio Complex, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Korea

TEL: +82-31-881-7400
FAX: +82-31-881-7524
IR Hotline: +82-31-780-7418

[Head Office] P&FOLUS Building, 442 Dosan-daero, Gangnam-gu, Seoul, Korea
[Business Hours] 09:00 AM – 06:00 PM

Affiliates

Global Healthcare

Business

CHA Biotech

History